THC:CBD ratios explained

There are an estimated 100,000+ medical cannabis patients in the UK. Find out if you qualify

THC:CBD ratios explained

THC:CBD ratios explained - MCPH patient guide cover

Share This Story

Facebook-f Twitter Youtube Linkedin-in

Table of Contents

THC:CBD ratios are one of the easiest parts of medical cannabis to misunderstand. A ratio can tell you something about the relative balance of THC and CBD in a product, but it does not tell you whether that product is right for you, what the prescribed dose would be, whether you can drive, or whether side effects will happen.

This guide explains ratio language without turning it into product-choice advice. Your specialist prescriber remains responsible for suitability, route, product choice, dose and monitoring.

For the wider UK access route, start with the MCPH patient guide. For related context, read medical cannabis oil vs flower and THC side effects and impairment.

What a THC:CBD ratio means

A THC:CBD ratio compares the relative amount of THC to CBD. A 1:1 product has a broadly balanced relationship between THC and CBD. A high-THC, low-CBD product has more THC relative to CBD. A CBD-dominant product has more CBD relative to THC.

That is the simple part. The important part is what the ratio does not tell you.

A ratio does not tell you:

  • the dose
  • the route
  • the full formulation
  • how you will respond
  • whether the product is suitable
  • whether side effects will happen
  • whether you can drive or work safely
  • whether it is legal for your circumstances

Ratio is one part of a clinical decision. It is not the decision.

Why the market can make ratios confusing

One reason THC:CBD ratios confuse patients is that the wider cannabis market has often rewarded high THC. In non-medical and consumer markets, stronger THC products can be perceived as better value or better quality because a smaller amount may feel more noticeable. That market pressure has encouraged THC-dominant products and has often pushed CBD and other cannabinoid-rich profiles into the background.

This is not only a patient impression. Research on cannabis potency has documented rising THC levels over time, and some analyses argue that commercial markets can overshoot THC compared with ratios often discussed in therapeutic contexts.

Medical cannabis is different because the goal is not simply stronger. A high-THC product is not automatically a better medicine. A low-CBD, high-THC flower may be appropriate for one patient and unsuitable for another. Balanced or CBD-rich products may be discussed for different clinical reasons. The point is not to chase the highest THC number. The point is to understand what the prescriber is trying to achieve and what risks are being managed.

There is also a useful history here. Heritage and landrace cannabis populations were not all bred around the same modern high-THC target. Some carried different cannabinoid balances, terpene patterns and minor-cannabinoid profiles. Over the last decade, CBD-focused breeding has also made CBD-rich and balanced cultivars more visible in legal and medical markets. That does not mean a heritage label, terpene profile or minor cannabinoid makes a product clinically suitable. It simply helps explain why ratio language is more complicated than high THC versus low THC.

In the current UK medical market, patients may hear about THC-dominant, balanced and CBD-rich options, depending on stock, prescribing policy and clinical suitability. Exact availability changes and should not be treated as a shopping list. Specific products should only be discussed with up-to-date information and appropriate clinical or pharmacy context.

The patient point is simple: ratios are a map of balance, not a scoreboard. More THC does not mean better treatment. More CBD does not mean no risk. A balanced product is not automatically gentle. The right question is what the ratio means in your prescription and your life.

What THC contributes

THC is the cannabinoid most associated with intoxication, impairment and psychoactive effects. In prescribed medical cannabis, THC may be clinically relevant for some patients, but it also brings risks that need screening and monitoring.

Those risks can include sleepiness, dizziness, anxiety, panic, paranoia, impaired concentration, changes in mood, palpitations or worsening mental health symptoms in some people. The exact risk depends on the person, product, route, dose, medical history and other medicines.

This is why mental health history matters. A prescriber may ask about psychosis, schizophrenia, mania, bipolar disorder, severe depression, suicidality, substance-use concerns or previous difficult reactions to cannabis. Read MCPH’s guide to medical cannabis and mental health screening for more context.

What CBD contributes

CBD is often talked about as the calmer cannabinoid, but that can become misleading. CBD is not the same as THC, and it does not usually produce the same intoxication profile, but it can still matter clinically.

CBD can interact with other medicines. It can also be part of a prescribed formulation where the full product, dose, route and monitoring plan matter. Patients should tell the prescriber about prescribed medicines, over-the-counter medicines, supplements, shop-bought CBD products and any non-prescribed cannabis use.

Do not assume that adding CBD cancels out THC risk. A balanced ratio can still contain THC. If THC is present, impairment and side effects still need to be considered.

Why ratios do not equal dose

Two products can have the same THC:CBD ratio but different strengths. A small amount of one product and a larger amount of another product can expose a patient to different amounts of THC and CBD even if the ratio label looks similar.

Route also matters. Oil, flower and other formulations are used differently and reviewed differently. MCPH has a separate guide to medical cannabis oil vs flower for patients who want to understand form differences without turning them into a recommendation.

Because ratio does not equal dose, patients should not use online ratio charts to self-select a product or adjust treatment. If you are prescribed medical cannabis, follow the plan from your prescriber and ask the clinic or pharmacy if the label or instructions are unclear.

Useful questions to ask a prescriber

You can ask informed questions without trying to choose the product yourself:

  • What does this THC:CBD ratio mean in this prescription?
  • What side effects should I watch for?
  • What would count as impairment?
  • How does my mental health history affect suitability?
  • Do any of my medicines or supplements raise interaction concerns?
  • What should I do if symptoms worsen?
  • When will the plan be reviewed?

These questions keep the discussion practical. They also help the prescriber explain the reasoning behind a plan.

Ratio language and driving

A ratio does not tell you whether you are safe or legally protected to drive. THC can impair driving, and UK drug-driving law is a separate issue from whether a medicine was prescribed.

If driving matters for you, raise it directly with the prescriber before starting treatment and whenever the treatment plan changes. MCPH has a separate guide to medical cannabis and driving in the UK and a guide to THC side effects and impairment.

FAQ

Is a 1:1 THC:CBD ratio safer?

Not automatically. A 1:1 ratio may sound balanced, but safety depends on the product, dose, route, patient history, medicines and monitoring. It can still involve THC-related impairment or side effects.

Is CBD-dominant medical cannabis risk-free?

No. CBD is different from THC, but it can still interact with medicines and should be discussed with the prescriber, especially if you take other prescribed medicines or supplements.

Does a high-THC product work better?

Do not assume that. Higher THC is not a general marker of better treatment. The wider market has often treated high THC as a quality signal, but medical prescribing should not work like a strength contest. Higher THC may also increase side-effect or impairment concerns. Suitability is a clinical decision.

Are balanced or CBD-rich strains available?

Patients may hear about balanced and CBD-rich options in the UK medical market, as well as THC-dominant options. Availability changes, and this guide should not be used to choose a strain or product. Ask the prescriber what the cannabinoid balance is meant to do in your plan.

Do landrace or heritage cultivars mean better medicine?

No. Heritage, landrace, terpene and minor-cannabinoid context can help explain why cannabis chemistry is varied, but it does not prove that a product is suitable for a patient. Suitability stays with the prescriber.

Can I choose a ratio myself?

You can ask what a ratio means and discuss concerns or preferences. The specialist prescriber decides whether any ratio, product, form, route or dose is suitable.

Does the ratio decide whether I can drive?

No. Ratio does not provide driving clearance. THC, impairment, prescription status, legal rules and individual response all matter, and you should discuss driving with your prescriber.

Sources

Where to go next

Author picture

Read the eligibility guide for medical cannabis in the UK

Read the eligibility guide

Click here